RESUMO
Objective To investigate the relationship between the expression of serum antigen KI-67 (ki67) and the clinicopathological characteristics of breast cancer patients, and to demonstrate the consistency between serum ki67 detection and immunohistochemical staining (IHC) in breast cancer patients. Methods The study enrolled 10 healthy women, 10 patients with benign breast masses and 86 with invasive breast cancer. ELISA was used to detect the relationship between serum ki67 levels and clinicopathological characteristics. Meanwhile, IHC was performed to study the relationship between the expression of ki67 and the clinicopathology in breast cancer tissues. Results The serum ki67 level in the healthy women was similar with the benign breast patients. But, the serum ki67 level in the breast patients significantly increased. The serum ki67 level in the breast cancer patients was closely related to lymph node metastasis, and was not obviously related to other clinicopathological features. The high expression of ki67 in breast cancer tissues was related to tumor size, histological grade, lymph node metastasis, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2(HER2), while it is not related with the age of patients. Conclusion The serum ki67 level is higher in breast cancer patients, but the test result alone was not as valuable as IHC in predicting the clinical diagnosis and treatment for breast cancer patients.
